Abstract
Erythropoietin (EPO) was first characterized as a hematopoietic growth factor and has been in clinical use as such for more than a decade. The expression of EPO and its receptor in brain tissue, cultured neurons and astrocytes along with its neuroprotective potential in several experimental models of stroke expands its biological role beyond hematopoiesis [1–5].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, Itri LM, Cerami A (2000) Proc Natl Acad Sci USA 97:10526–10531
Lewczuk P, Hasselblatt M, Kamrowski-Kruck H, Heyer A, Unzicker C, Sirén AL, Ehrenreich H (2000) Neuroreport 11:3485–3488
Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R (1998) Proc Natl Acad Sci USA 95:4635–4640
Sirén A-L, Fratelli M, Brines ML, Goemans C, Casagrande S, Lewczuk P, Keenan S, Gleiter C, Pasquali C, Capobianco A et al (2001 a) Proc Natl Acad Sci USA 98:4044–4049
Sirén A-L, Knerlich F, Poser W, Gleiter C, Brück W, Ehrenreich H (2001 b) Acta Neuropathologi-ca 101:271–276
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Ehrenreich, H., Sirén, A.L. (2004). Erythropoietin: A Beneficial Approach to Neuroprotection in Stroke. In: Buchan, A.M., Ito, U., Colbourne, F., Kuroiwa, T., Klatzo, I. (eds) Maturation Phenomenon in Cerebral Ischemia V. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18713-1_6
Download citation
DOI: https://doi.org/10.1007/978-3-642-18713-1_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-40874-1
Online ISBN: 978-3-642-18713-1
eBook Packages: Springer Book Archive